Loading
Radiation turns the irradiated tumour into a vaccine; immunotherapy spreads the response.
This combination pairs SBRT / SABR (stereotactic radiotherapy) and other radiotherapy with Immune checkpoint inhibitors: radiation turns the irradiated tumour into a vaccine and immunotherapy spreads the response. Radiation induces immunogenic cell death, cGAS-STING innate sensing, MHC upregulation and antigen release, and PD-L1 rises afterwards, which checkpoint blockade counters. Phase 3 trials are positive in consolidation settings, notably PACIFIC (Durvalumab after chemoradiation in Non-small-cell lung cancer, with overall survival benefit), KEYNOTE-A18 in Cervical cancer and NRG/RTOG trials. The Abscopal effect with SBRT plus immunotherapy is real but inconsistent, with PEMBRO-RT positive and other trials negative, so timing, dose and site matter.
Shares An oncology patent pool for combination trials across companies, cGAS-STING innate sensing, Pembrolizumab, Immune checkpoint inhibitors.
Shares Abscopal effect, SBRT / SABR (stereotactic radiotherapy), Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Abscopal effect, SBRT / SABR (stereotactic radiotherapy), Immune checkpoint inhibitors.
Shares Durvalumab, Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares An oncology patent pool for combination trials across companies, A neutral platform trial for radiotherapy plus immunotherapy combinations.
Shares Durvalumab, Pembrolizumab, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Durvalumab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares PD-1 blockade + chemoradiation (locally advanced cervical cancer), Cervical cancer, Pembrolizumab, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/